HBX 19,818 was later shown to covalently bind the active site of USP7, selectively and irreversibly inhibiting its activity, resulting in increased p53 levels in human cancer cells, inducing apoptosis in a dose-dependent manner [252]. Here, TP53 is linked to cancer.